PetVivo Holdings

Spryng is an injectable veterinary medical device made of sterilized, micronized gelatin particles suspended in phosphate-buffered saline. It is injected intra-articularly into osteoarthritic joints of dogs (and cats under veterinary discretion), where the particles adsorb onto damaged cartilage and act as a lubricating, shock-absorbing cushion. The FDA's Center for Veterinary Medicine cleared Spryng via a 510(k) premarket notification as a device intended to restore joint function; the company positions it as a single in-clinic procedure that may last months depending on the animal's disease severity and activity level.

John Lai serves as Chief Executive Officer and is the primary executive spokesperson for the company. PetVivo is headquartered in Minneapolis, Minnesota, and its common stock trades on the Nasdaq Capital Market under the ticker PETV. Day-to-day operations combine R&D on gelatin-microparticle applications with a national veterinary sales effort run through independent distributors.

PetVivo is an operating company — an animal-health biomedical firm that designs, develops, and commercializes medical devices for companion animals. It is not a family office or an investment fund, though it raises capital through public equity offerings and has been listed on Nasdaq since a reverse-merger transaction in 2020 that took it public. The firm's revenue comes from selling Spryng units to veterinary clinics, not from managing third-party assets.

Spryng holds 510(k) clearance from the FDA's Center for Veterinary Medicine, which classifies it as a Class II veterinary medical device. This clearance path allows PetVivo to market Spryng for intra-articular use in managing non-infectious sources of joint pain in dogs and cats, but major disease-modifying claims require data from controlled clinical studies submitted post-market or through a separate NADA pathway. The company has completed a pivotal field-effectiveness study and routinely presents efficacy data at academic veterinary conferences.

PetVivo has described a potential human-therapeutics pipeline based on its gelatin-microparticle platform, but no Investigational New Drug application or human clinical trial has been publicly announced. The companion-animal market remains the company's sole commercial focus as of mid-2025, and revenue is derived exclusively from veterinary sales of Spryng.

According to American Veterinary Medical Association data, approximately 14 million dogs in the United States are diagnosed with osteoarthritis annually, and many more go untreated due to the compliance burden of daily oral medications. PetVivo targets the segment of this market that general-practice veterinarians manage in-clinic — pets where owners seek an intervention beyond chronic NSAID use but do not pursue surgical joint replacement. The company cites a total addressable U.S. companion-animal osteoarthritis market of $3.3 billion (per corporate investor presentations).

Unlike diversified animal-health conglomerates that sell pharmaceuticals, vaccines, parasiticides, and diagnostics across multiple species and geographies, PetVivo is a single-product-line company focused on one differentiated biomaterial. Its device classification and in-clinic injection model sit outside the daily-pill or chronic-injection regimens that define the large players' pain-management portfolios. The company's small scale means it relies on a concentrated network of regional veterinary distributors rather than a large in-house salesforce, which constrains market reach but keeps the burn-rate profile lower.